Drawing for MODEX

USPTO serial 99719206

MODEX

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
ZAVALA DIEK, JOSEPH MARCO
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with MODEX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jill Anderfuren

Jill Anderfuren Lewis Brisbois Bisgaard & Smith LLP550 West Adams Street, Suite 300Chicago, IL 60661United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals for the prevention and treatment of cancer and infectious diseases; therapeutic pharmaceuticals for the prevention and treatment of cancer and infectious diseases; immunopharmaceuticals for the prevention and treatment of cancer and infectious diseases; vaccines; therapeutic vaccines; multispecific antibodies for medical therapeutic purposes; multi-specific immunotherapeutic pharmaceutical compositions for the prevention and treatment of cancer and infectious diseasesACTIVE—
042Medical research; Research and development of pharmaceuticals; research and development services in the field of antibodies, and immunotherapies for the treatment of cancer and infectious diseases; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; pharmaceutical research and development; vaccine research and development services; research and development in the field of immunotherapyACTIVEApr 1, 2024

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 1, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 1, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 26, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 5, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 4, 2026DOCKASSIGNED TO EXAMINER—
Aug 3, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 23, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 23, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance